Nivolumab plus ipilimumab is being reviewed by the FDA as a first-line treatment for advanced colorectal cancer, with a ...

A breakthrough cancer treatment plan could be a "cure" for a death sentence form of the disease. An experimental new ...

The FDA has accepted the sBLA for nivolumab (Opdivo) plus ipilimumab (Yervoy) as a potential first-line treatment for advanced MSI-H or dMMR CRC.

A clinical trial demonstrates that personalised cancer vaccines effectively target mutations in high-risk kidney cancer, ...

(RTTNews) - Innovent Biologics Inc. (IVBXF.OB) announced that the New Drug Application or NDA for ipilimumab injection (anti-CTLA-4 monoclonal antibody) has been accepted by the Center for Drug ...

The US Food and Drug Administration (FDA) has accepted Bristol Myers Squibb’s (BMS) supplemental biologics licence ...

The article by Doshi et al entitled “Real-World Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Nivolumab Plus Ipilimumab in the United States” (JCO Clin Cancer ...

A team has developed scSPOT, a new technique that reveals how immune cells called Tregs simultaneously control the immune system. The team identified key immune cells controlled by Tregs and found ...

The following is a summary of “First-in-human evaluation of memory-like NK cells with an IL-15 super-agonist and CTLA-4 blockade in advanced head and neck cancer,” published in the February 2025 issue ...

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. You must make your comments ...

Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703 Supported in part by University of Colorado Shared Resources ...